1. Articles in category: Treatment

    1-24 of 147 1 2 3 4 5 6 7 »
    1. Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.

      Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.

      J Pediatr Surg. 2017 Aug 26;:

      Authors: Kawakubo N, Tanaka S, Kinoshita Y, Tajiri T, Yonemitsu Y, Taguchi T

      Abstract PURPOSE: In preclinical trails, we reported the antitumor effect of dendritic cells activated with Sendai virus (rSeV/DC) combined with γ-irradiation against neuroblastoma.

      Read Full Article
    2. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Expert Opin Investig Drugs. 2017 Sep 14;:

      Authors: Amoroso L, Haupt R, Garaventa A, Ponzoni M

      Abstract INTRODUCTION: Neuroblastoma (NB) is an embryonal tumor originating from undifferentiated neural crest cell, highly heterogeneous ranging from spontaneous regression to progression despite multimodal treatments.

      Read Full Article
      Mentions: Treatment
    3. Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma.

      Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Sep 08;:

      Authors: Whittle SB, Punia JN, López-Terrada D, Gaikwad A, Hampton OA, Heczey A

      Abstract Neuroblastoma is the most common extracranial malignancy of childhood.

      Read Full Article
      Mentions: Treatment
    4. Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.

      Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jan;39(1):e33-e35

      Authors: Cash T, Alazraki A, Qayed M, Katzenstein HM

      Abstract Patients with high-risk neuroblastoma remain a therapeutic challenge with significant numbers of patients failing to respond sufficiently to initial therapy. These patients with poor response to induction are considered as ultra high-risk and are in need of novel treatment strategies.

      Read Full Article
      Mentions: Treatment
    5. Study shows incisionless surgery with MR-HIFU effective in destroying painful bone tumors

      Study shows incisionless surgery with MR-HIFU effective in destroying painful bone tumors

      Doctors from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System have completed a clinical trial that demonstrates how osteoid osteoma, a benign but painful bone tumor that commonly occurs in children and young adults, can be safely and successfully treated using an incisionless surgery method called magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU).

      Read Full Article
      Mentions: Surgery
    6. Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.

      Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.

      Clin Cancer Res. 2017 Aug 22;:

      Authors: Sanmartín E, Muñoz L, Piqueras M, Sirerol JA, Berlanga P, Cañete A, Castel V, Font de Mora J

      Abstract PURPOSE: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20-30%) undergo consecutive recurrences with poor outcome.

      Read Full Article
    7. p53 non-genotoxic activation and mTORC1 inhibition lead to effective combination for neuroblastoma therapy.

      p53 non-genotoxic activation and mTORC1 inhibition lead to effective combination for neuroblastoma therapy.

      Clin Cancer Res. 2017 Aug 18;:

      Authors: Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone KA, Schild L, Aviles-Padilla K, Nikzad R, Zhang Y, Chakraborty R, Molenaar JJ, Vasudevan S, Sheehan V, Kim ES, Paust S, Shohet JM, Barbieri E

      Read Full Article
    8. RACE for Children Act Becomes Law!

      RACE for Children Act Becomes Law!

      WASHINGTON, Aug. 19, 2017 /PRNewswire/ -- Yesterday, the RACE for Children Act became law, ensuring that novel and exciting new cancer drugs will now be developed not only for adults, but also for children with cancer. Nancy Goodman, CEO of Kids v Cancer stated, "One of the greatest...

      Read Full Article
    9. Research Suggests Turmeric Could Help Fight Cancer in Infants

      Research Suggests Turmeric Could Help Fight Cancer in Infants

      Jessica Miley Turmeric, the spice commonly associated with Indian cooking, has been used by researchers as a treatment for infants with cancer. Neuroblastoma is the most common cancer in infants, affecting 1 in every 7000 children. 90% of the cases of neuroblastoma is found in children under the age of 5, it is a rarely diagnosed in adults.

      Read Full Article
      Mentions: Treatment
    10. Longitudinal parental preferences for late effects communication during cancer treatment

      Few studies have investigated parent preferences for late effects communication during pediatric cancer treatment. We used questionnaire data to assess whether parental preferences for late effects information change over the year after diagnosis. Most parents found this information to be very/extremely important at baseline, assessed soon after diagnosis, (94%, 153/162), 4 months (91%, 147/162), and 12 months (96%, 156/163).

      Read Full Article
      Mentions: Treatment
    11. Neurological Complications of Childhood Cancer.

      Neurological Complications of Childhood Cancer.

      Semin Pediatr Neurol. 2017 Feb;24(1):60-69

      Authors: Weaver L, Samkari A

      Abstract Though the treatment of pediatric cancers has come a long way, acute and chronic effects of cancer are still affecting the life of many children. These effects may be caused not only by the malignancy itself but also by the interventions used for the purpose of treatment.

      Read Full Article
    12. New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      The Treehouse Childhood Cancer Initiative researchers at UC Santa Cruz Genomics Institute and the St. Baldrick's Foundation are making a 11,000+ tumor database available for use by all researchers in the pediatric cancer community and beyond in our continued battle to take childhood back from cancer. The database contains RNA-Seq gene expression data, as well as age, disease, and sex.

      Read Full Article
      Mentions: Genetics
    13. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.

      Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.

      Clin Nucl Med. 2017 Jul 29;:

      Authors: Pandit-Taskar N, Zanzonico P, Hilden P, Ostrovnaya I, Carrasquillo JA, Modak S

      Read Full Article
    14. New strategy against childhood cancer

      New strategy against childhood cancer

      Neuroblastoma is a cancer in children that originates in the sympathetic nervous system and has a high mortality. Current treatment includes chemotherapy and radiotherapy with their potentially severe side effects; there is therefore an urgent need for a new improved drug. One potential treatment strategy is to use a drug to target deviant molecular signalling caused by changes in genes.

      Read Full Article
    15. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

      Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature.

      Read Full Article
    16. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2{alpha} to tumor suppression [Medical Sciences]

      Neuroblastoma is a pediatric cancer characterized by variable outcomes ranging from spontaneous regression to life-threatening progression. High-risk neuroblastoma patients receive myeloablative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid differentiation treatment. However, the overall survival remains low; hence, there is an urgent need for alternative therapeutic approaches. One feature...

      Read Full Article
    17. NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers Posted: July 24, 2017 240-760-6600 Credit: National Cancer Institute Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial.

      Read Full Article
      Mentions: Treatment COG
    18. MOlecular Screening for CAncer Treatment Optimization (MOSCATO-01) in pediatric patients: A single institutional prospective molecular stratification trial.

      MOlecular Screening for CAncer Treatment Optimization (MOSCATO-01) in pediatric patients: A single institutional prospective molecular stratification trial.

      Clin Cancer Res. 2017 Jul 21;:

      Authors: Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N, Vielh P, Varlet P, Balogh Z, Abbou S, Allorant A, Valteau-Couanet D, Sarnacki S, Galmiche L, Meurice G, Minard-Colin V, Grill J, Brugières L, Dufour C, Gaspar N, Michiels S, Vassal G, Soria JC, Geoerger B

      Read Full Article
      Mentions: Treatment
    19. NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      The nationwide precision medicine trial will enroll children and adolescents with advanced cancers that haven’t responded to standard therapy to explore treatments targeted at specific genetic mutations.

      Read Full Article
      Mentions: Treatment COG
    20. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.

      Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.

      Genes Chromosomes Cancer. 2017 Jan;56(1):28-41

      Authors: Marrano P, Irwin MS, Thorner PS

      Abstract Amplification of the MYCN gene in neuroblastoma is associated with a poor prognosis and is considered to remain unchanged in post-treatment specimens and metastases.

      Read Full Article
    21. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Biochem Biophys Res Commun. 2017 Jul 12;:

      Authors: Li Y, Zhuo B, Yin Y, Han T, Li S, Li Z, Wang J

      Abstract Chemotherapy is one of the few effective choices for patients with neuroblastoma. However, the development of muti-drug resistance (MDR) to chemotherapy is a major obstacle to the effective treatment of advanced or recurrent neuroblastoma.

      Read Full Article
    22. Moringa isothiocyanate complexed with α-cyclodextrin: a new perspective in neuroblastoma treatment.

      Moringa isothiocyanate complexed with α-cyclodextrin: a new perspective in neuroblastoma treatment.

      BMC Complement Altern Med. 2017 Jul 14;17(1):362

      Authors: Giacoppo S, Iori R, Rollin P, Bramanti P, Mazzon E

      Abstract BACKGROUND: Several lines of evidence suggest the consume of natural products for cancer prevention or treatment. In particular, isothiocyanates (ITCs) exerting anti-cancer properties, have received great interest as potential chemotherapeutic agents.

      Read Full Article
      Mentions: Treatment LDH
    23. Nanoparticle delivery of curcumin induces cellular hypoxia and ROS-mediated apoptosis via modulation of Bcl-2/Bax in human neuroblastoma.

      Nanoparticle delivery of curcumin induces cellular hypoxia and ROS-mediated apoptosis via modulation of Bcl-2/Bax in human neuroblastoma.

      Nanoscale. 2017 Jul 12;:

      Authors: Kalashnikova I, Mazar J, Neal CJ, Rosado AL, Das S, Westmoreland TJ, Seal S

      Abstract In this study, several formulations of nanoceria and dextran-nanoceria with curcumin, each demonstrated to have anti-cancer properties, were synthesized and applied as treatment for human childhood neuroblastoma.

      Read Full Article
      Mentions: Treatment MYCN
    1-24 of 147 1 2 3 4 5 6 7 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. General Informations in the News

    1. (3 articles) Treatment